Clinical and Economic Implications of Genetic Testing for Warfarin Management
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/19/2016 |
| Start Date: | August 2009 |
| End Date: | December 2016 |
The Hospital and Economics CERT: Project 1: The Clinical and Economic Implications of Genetic Testing for Warfarin Management
The purpose of this study is to explore how knowing genes that individuals inherit from
their parents can make warfarin dosing more safe and effective. This study is being done to
determine whether providing doctors with data on the genes their patients inherited and
warfarin dosing recommendations based on those genes affects the costs and outcomes of care
and after hospitalization for patients from different ethnic/racial backgrounds, and how
physicians use this information in decision making.
their parents can make warfarin dosing more safe and effective. This study is being done to
determine whether providing doctors with data on the genes their patients inherited and
warfarin dosing recommendations based on those genes affects the costs and outcomes of care
and after hospitalization for patients from different ethnic/racial backgrounds, and how
physicians use this information in decision making.
The overall goal of this project is to develop and assess the effectiveness and
cost-effectiveness of strategies that use genetic testing in the management of
anticoagulation among racially diverse hospitalized patients. The project has four specific
aims.
Aim 1: To contribute patients initiating therapy at the University of Chicago Medical Center
(UCMC) and affiliated hospitals to a genetic registry of a racially diverse set of patients
undergoing warfarin therapy.
Aim 2: To perform a randomized trial to determine the efficacy, costs and cost-effectiveness
of existing pharmacogenetic algorithms for the management of warfarin therapy among
hospitalized patients of all races.
Aim 3: To develop clinical pharmacogenetic algorithms for the management of warfarin therapy
among hospitalized African American patients.
Aim 4: To perform a randomized trial to determine and compare the efficacy, costs and
cost-effectiveness of existing clinical and non-racially tailored pharmacogenetic algorithms
to racially tailored pharmacogenetic algorithms for the management of warfarin therapy among
hospitalized African American patients.
cost-effectiveness of strategies that use genetic testing in the management of
anticoagulation among racially diverse hospitalized patients. The project has four specific
aims.
Aim 1: To contribute patients initiating therapy at the University of Chicago Medical Center
(UCMC) and affiliated hospitals to a genetic registry of a racially diverse set of patients
undergoing warfarin therapy.
Aim 2: To perform a randomized trial to determine the efficacy, costs and cost-effectiveness
of existing pharmacogenetic algorithms for the management of warfarin therapy among
hospitalized patients of all races.
Aim 3: To develop clinical pharmacogenetic algorithms for the management of warfarin therapy
among hospitalized African American patients.
Aim 4: To perform a randomized trial to determine and compare the efficacy, costs and
cost-effectiveness of existing clinical and non-racially tailored pharmacogenetic algorithms
to racially tailored pharmacogenetic algorithms for the management of warfarin therapy among
hospitalized African American patients.
Inclusion Criteria:
- warfarin-naive patients
- ages 18 and older
- are undergoing inpatient anticoagulation initiation with warfarin for diagnoses that
necessitate anticoagulation
Exclusion Criteria:
- patients who are not warfarin-naive
- 17 years of age or younger
We found this trial at
1
site
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
